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1. HYPERTENSION
Hypertension is a silent killer, currently affects approximately one billion adults
globally. Hypertension is an important risk factor for cardiovascular diseases and stroke
and  is  associated  with  metabolic  syndromes  including  insulin  resistance  and  lipid
abnormalities.  At  a  defining  cut  of  140/90  mmHg,  28-44% of  world  population  has
hypertension1. Estimated prevalence of hypertension is about 25% among urban adults
and 10% in the rural areas2. The life time risk for developing hypertension is estimated to
be up to 90%. It’s a condition, the blood pressure is elevated to an extend; where clinical
benefit  can  be  obtained  from  blood  pressure  lowering.  Components  used  for
determination are systolic and diastolic blood pressure. There is no clear cut off point
between hypertensive and normotensive subject.
 The blood pressure is a product of  cardiac output and the total  resistance of
peripheral system, of that high blood pressure arises as a result of increased resistance of
peripheral system due to constriction of small arterioles.  Hypertension is a condition, the
pressure that’s put on the walls of the arteries as blood is pumped through the circulatory
system. The circulation of blood through the veins and arteries is at certain pressure. In
natural limit it is not harmful. But with this pressure increase, heart is over worked and an
abnormal interior tissue growth can be developed in arteries. This cause further blocked
in passage of blood, leading to blood pressure increasing.
In many cases, genetic susceptibility to hypertension is observed. Hypertension is
twice common in subjects with hypertensive parents. Essential hypertension occurs four
times more frequently in blacks than whites. And in middle aged population males are
more frequent with hypertension than the females. 
Many drugs which are commonly using can cause high blood pressure as side
effect.  Some of  the  drugs  belongs to  the above category includes  non-steroidal  anti-
inflammatory drugs, contraceptives, steroids. Obesity causes high blood pressure due to
increased body weight  and additional  pressure  that  it  exerts  on the heart  and arterial
system. An unhealthy diet which is rich with salt and fats lack of dietary fibers along with
Ultra college of pharmacy, Madurai. Page 1
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a  secondary life  style  devoid  of  proper  exercise ,excessive  use  of  alcohol  ,  cigarette
smoking is an another culprit for hypertension.
Advanced medical  researchers  are  developing new methods to  lower  the high
blood pressure and it has gone to great lengths. Even the arterial hypertension is almost
never a serious health treat; doctors attempt to lower high blood pressure because it can
have serious long term consequences.
It’s was also shown that more than 64% of patients with hypertension also have
dyslipidemia and 47% of patients with dyslipidemia have hypertension3. Highly elevated
TGL levels are found in hypertensives on comparing with normotesives4. Patients with
hypertension frequently have additional cardiovascular risk5. Conversely hypertension is
a significant risk factor in patients with elevated cholesterol and diabetes6.
Strategies that reduce BP and lipid levels simultaneously are likely to lead to a
greater reduction in the incidence of CVD related events than treating either factor in
isolation.
A.1 DEFENITION 
Hypertension is defined as a sustained diastolic blood pressure greater than 90
mm Hg accompanied by an elevated systolic blood pressure greater than 140 mm Hg7.
Blood pressure is the force by which blood drives through blood vessels to supply oxygen
and nutrients to the body organs and carry away metabolites and waste materials. The
blood pressure is optimal if it is less than 120/80 mm Hg.  
A.2 ETIOLOGY
More than 90% of the patients having essential hypertension, it is a disorder of
unknown origin effect  the BP regulating mechanism. A subject  with family history of
hypertension is likelihood to develop hypertensive disease. Primary hypertension is four
times more frequently in blacks than in whites. Likely it observed more often in middle
aged male subjects than middle aged females. Many environmental factors like stressful
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life style , un-healthy diet , obesity , smoking and alcoholism, lack of proper exercise and
usage of drugs such as NSAID are predisposing factors to develop hypertension8.
A.3 CAUSES OF HYPERTENSION
 90-95% of hypertension is essential hypertension and 5-10% of hypertension 
belongs to Secondary hypertension. Causes of primary hypertension are not clearly 
unknown. Secondary hypertension is renal or endocrine diseases, vascular diseases. And 
the same may be arising due to the drugs.
` Endocrine  diseases  which  can  produce  secondary  hypertension  are
Acromegaly,Conn’s  syndrome,  Cushing’s  syndrome,  Phaeochromocytoma,  Pre
eclampsia. Vascular causes includes Fibro muscular hyperplasia,  renal artery atheroma
etc. Many drugs can also be leading factors for secondary hypertension. Adrenal steroids,
Antidepressants  Appetite  suppressants,Cocaine,Cyclosporine,  Erythropoietin,  Nasal
decongestants, NSAIDs, Oral contraceptives, Sympathomimeticsarethere in the category
of drugs which can induce hypertension9.
A.4COMPLICATIONS OF HYPERTENSION
MI
Stroke
Malignant hypertension
Dissecting aortic aneurysm 
Hypertensive nephrosclerosis
Peripheral vascular disease10
A.4 a) MYOCARDIAL INFRACTION12
A heart attack occurs when blood flow to a part of heart is blocked for a long
enough time that part of the heart muscle is damaged or dies. The medical term for this is
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myocardial infarction. Most heart attacks are caused by a blood clot that blocks one of the
coronary arteries. The coronary arteries bring blood and oxygen to the heart. If the blood
flow is blocked, the heart is starved of oxygen and heart cells die .A hard substance called
plaque  can  build  up  in  the  walls  of  coronary  arteries.  This  plaque  is  made  up  of
cholesterol and other cells. Chest pain is the most common symptom of a heart attack.
One may feel the pain in only one part of your body, or it may move from your chest to
arms, shoulder, neck, teeth, jaw, belly area, or back. Other symptoms of a heart attack can
include  anxiety,  cough,  fainting,  light  headedness,  dizziness,  nausea,  vomiting,  and
shortness of breath, sweating, palpitation11. 
A.4 b) STROKE
A stroke  happens  when  blood  flow  to  a  part  of  the  brain  stops.  A stroke  is
sometimes  called  a "brain  attack."If  blood  flow  is  stopped  for  longer  than  a  few
seconds, the brain cannot get blood and oxygen. Brain cells can die, causing permanent
damage. There are two major types of stroke, ischemic stroke and hemorrhagic stroke.
Ischemic stroke occurs when a blood vessel that supplies blood to the brain is blocked by
a  blood  clot.  This  may  happen  in  two  ways,  thrombotic  stroke  or  embolic  stroke.
Ischemic  strokes  may  be  caused  by  clogged  arteries.  Fat,  cholesterol,  and  other
substances  collect  on  the  artery  walls,  forming  a  sticky  substance  called  plaque.  A
hemorrhagic stroke occurs when a blood vessel in part of the brain becomes weak and
bursts open, causing blood to leak into the brain. Some people have defects in the blood
vessels of the brain that make this more likely.
A.4 c) MALIGNANT HYPERTENSION 
Malignant hypertension is very high blood pressure that comes on suddenly and
quickly.  The  lower  (diastolic)  blood  pressure  reading,  which  is  normally  around  80
mmHg, is often above 130 mmHg.The disorder affects about 1% of people with high
blood  pressure,  including  both  children  and  adults.  It  is  more  common  in  younger
adults.It also occurs in people with collagen vascular disorders, kidney problems, toxemia
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of  pregnancy.  High  risk  for  malignant  hypertension  includes  kidney  failure,  renal
hypertension.
A.4 d) DISSECTING AORTIC ANEURYSM 
Aortic dissection occurs when a tear in the inner wall of the aorta causes blood to
flow between the layers of the wall of the aorta, forcing the layers apart. In most cases
this is associated with severe characteristic chest or abdominal pain described as "tearing"
in character, and often with other symptoms that result from decreased blood supply to
other organs.  Aortic dissection is  a medical  emergency and can quickly lead to death,
even  with  optimal  treatment,  as  a  result  of  decreased  blood  supply  to  other
organs, cardiac  failure,  and  sometimes rupture  of  the  aorta.  Aortic  dissection  is  more
common  in  those  with  a  history  of high  blood  pressure,  a  known thoracic  aortic
aneurysm, and in  a  number of conditions  that  affect  blood vessel  wall  integrity such
as Marfan syndrome and the vascular subtype of Ehlers–Danlos syndrome. The treatment
of aortic dissection depends on the part of the aorta involved. Surgery is usually required
for dissections that  involve the aortic arch, while dissections of the part  further away
from the heart  may be treated with  blood pressure lowering only.Aortic  dissection is
relatively rare, occurring at an estimated rate of 2–3.5 per 100,000 people every year. It is
more common in males. Mean age at diagnosis is 63, although all age groups may be
affected. Many cases of aortic dissection (40%) lead to death so rapidly that the person
doesn't make it to hospital in time.
A.4 e) HYPERTENSIVE NEPHROSCLEROSIS 
Hypertensive nephropathy or hypertensive nephrosclerosis, or Hypertensive renal
disease is  a medical  condition referring to damage to  the kidney due to chronic high
blood pressure.  It  should be distinguished from renovascular hypertension which is  a
form of secondary hypertension.In the kidneys, as a result of benign arterial hypertension,
hyaline  (pink,  amorphous,  homogeneous  material)  accumulates  in  the  wall  of  small
arteries and arterioles, producing the thickening of their walls and the narrowing of the
lumina  hyaline  arteriolosclerosis.  Consequent  ischemia  will  produce  tubular  atrophy,
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interstitial  fibrosis,  glomerular  alterations  and  periglomerular  fibrosis.  In  advanced
stages,renal  failure  will  occur.  Functional  nephrons  have  dilated  tubules,  often  with
hyaline casts in the lumens. Additional complications often associated with hypertensive
nephropathy include glomerular damage resulting in protenuria and hematuria12.
A.4 f) PERIPHERAL VASCULAR DISEASE
Peripheral vascular disease is a narrowing of blood vessels that restricts blood
flow. It mostly occurs in the legs, but is sometimes seen in the arms. Peripheral vascular
disease includes a group of diseases in which blood vessels become restricted or blocked.
Typically,  the  patient  has  peripheral  vascular  disease  from atherosclerosis.
Atherosclerosis is  a  disease in which fatty plaques form in the inside walls  of  blood
vessels.  Other  processes,  such as blood clots,  further  restrict  blood flow in the blood
vessels. Both veins and arteries may be affected, but the disease is usually arterial. All the
symptoms and consequences of peripheral vascular disease are related to restricted blood
flow. Peripheral vascular disease is a progressive disease that can lead to gangrene of the
affected area. Peripheral vascular disease may also occur suddenly if an embolism occurs
or  when  a  blot  clot  rapidly  develops  in  a  blood  vessel  already  restricted  by  an
atherosclerotic plaque, and the blood flow is quickly cut off. There are many causes of
peripheral vascular disease. One major risk factor is smoking cigarettes. Other diseases
predispose  patients  to  develop  peripheral  vascular  disease.  These  include  diabetes,
Burger’s disease, hypertension, and Reynaud’s disease. The main symptom is pain in the
affected area. Early symptoms include an achy, tired sensation in the affected muscles.
Since  this  disease  is  seen  mainly  in  the  legs,  these  sensations  usually  occur  when
walking.  The  symptoms may disappear  when resting.  As the disease becomes worse,
symptoms occur even during light exertion and, eventually, occur all the time, even at
rest. In the severe stages of the disease the leg and foot may be cold to the touch and will
feel numb. The skin may become dry and scaly. If the leg is even slightly injured, ulcers
may form because, without a good blood supply, proper healing cannot take place. At the
most severe stage of the disease, when the blood flow is greatly restricted, gangrene can
develop in those areas lacking blood supply. In some cases, peripheral vascular disease
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occurs suddenly. This happens when an embolism rapidly blocks blood flow to a blood
vessel. The patient will experience a sharp pain, followed by a loss of sensation in the
affected area. The limb will become cold and numb, and loose color or turn bluish.
The  most  common and  important  CV complication  associated  with  hypertension  are
stroke and myocardial infarction, Increase of  5 mm Hg diastolic pressure from usual
range shows 35- 40% increased risk of stroke and similar but less steep association for
coronary heart disease . According to Framingham heart study subjects with BP values
between 130 to 139 and 85 to 89 mm Hg are associated with more than two fold increase
in relative risk from CVD when comparing subjects with a BP level less than 120/80 mm
Hg.
A.5 RISK FACTORS OF CVD
• Hypertension 
• Elevated LDL or low HDL
• Age 
• Diabetes mellitus
• Renal disease
• Family history
• Obesity
• Life style 13
Management  of  hypertension  and  other  risk  factors  is  essential  to  reduce  the
morbidity and mortality risks arise due to hypertension.
A.6 CLASSIFICATION OF BLOOD PRESSURE
Table1. 14
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Classification Systolic (mm Hg) Diastolic (mm Hg)
Normal <120 <80
Prehypertension 120–139 80–89
Stage 1 hypertension 140–159 90–99
Stage 2 hypertension ≥160 ≥100
Table2.
People  with  stage  1  and stage  2  are to  be  treated.  The  goal  of  treatment   in
individuals without Compelling indications for use of antihypertensive  drugs is >140/90
mm hg , and the same in subjects with prehypertension is to lower the BP with life style
changes to prevent it’s further progression15.
A.7 PREVENTION OF HYPERTENSION 
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By preventing the rise in BP, hypertensive risk like cardiovascular diseases, renal
diseases, stoke, and the hypertension itself can be reduce or minimize. For that preventive
measures to minimize or avoid the causing factors or risk factors of hypertension should
be introduced to the specific population. The causing factors that are to be avoided or
minimized for attaining the aim of prevention of hypertension includes smoking, intake
of sodium rich and fatty diet, excess of alcohol intake, excess of body weight18 etc. A diet
which is rich with fruits and vegetables, with sufficient potassium is suggested   with an
improved  physical  activity  to  minimize  the  rise  in  BP.  It  is  mainly  meant  for  the
population who belong to prehypertension. It is observed and estimated from studies that
it can be attain a reduction of 8% in mortality rates with stroke, 5% reduction in mortality
due to CAD, by reducing 3mm Hg of systolic BP16.
1. Engage in regular aerobic physical activity such as brisk walking (at least 30 minutes
per day, most days of the week).
2. Maintain normal body weight for adults (body mass index 18.5 – 24.9 kg/m2).
3. Limit alcohol consumption to no more than 1 oz (30 ml) ethanol (e.g., 24 oz    [720 ml 
of beer, 10 oz [300 ml] of wine, or 2 oz [60 ml] 100-proof whiskey) per day in most men 
and to no more than 0.5 oz (15 ml) of ethanol per day in women and lighter weight 
persons.
4. Reduce dietary sodium intake to no more than 100 m mol per day (approximately 2.4 g
of sodium or 6 g of sodium chloride).
5. Maintain adequate intake of dietary potassium (more than 90 m mol [3,500 mg] per
day).
6. Consume a diet that is rich in fruits and vegetables and in low fat dairy products with a
reduced  content  of  saturated  and  total  fat  (Dietary Approaches  to  Stop Hypertension
[DASH] eating plan).
A.8 DIAGNOSTIC PROCEDURES AND LABORATORY TESTS
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The  primary  parameter  for  diagnosing  of  primary  hypertension  is  physical
examination of BP. The arteriolar  narrowing, focal  arteriolar  narrowing, arteriovenous
nicking, and retinal hemorrhages, exudates, and infarcts are examined for hypertensive
emergency.  Cardiopulmonary examination are done for  identifying the abnormality in
heart rate or rhythm, left ventricular (LV) hypertrophy, pericardial heave, third and fourth
heart  sounds.  Peripheral  vascular  examinations  are  performed  to  evidence  of
atherosclerosis,  aortic or abdominal bruits,  distended veins, and edema17.  Renal artery
stenosis  can  be  indicated  by  abdominal  systolic-diastolic  bruit.   Hypokalemia  may
suggest  mineralocorticoid-induced  hypertension.  The  presence of  protein,  blood cells,
and casts in the urine are examined for presence of renovascular disease.
Laboratory tests recommended prior to initiating drug therapy include urinalysis,
serum chemistries (sodium, potassium, creatinine, fasting glucose, fasting lipid panel),
and a 12-lead electrocardiogram (ECG).
These laboratory tests are recommended to identify the risk factors, and the 
metabolic changes that are produced due to treatment. More extensive testing for 
identifiable cause is not generally indicated unless Bp control is not achieved or the 
clinical and routine laboratory evaluation strongly suggests an identifiable secondary 
cause. 
A.9 PATHOPYSIOLOGY OF HYPERTENSION
Hypertension  is  a  heterogeneous  disorder.  The  underlying  mechanism  for
hypertensionthat may have specific cause which is known as secondary hypertension and
may be a pathophysiologic mechanism of unknown etiology which is known as primary
or  essential  hypertension.10%  of  total  hypertension  cases  belong  to  the  secondary
hypertension, renovascular disease or chronic kidney disease is the major causing factor
for  secondary hypertension.The  other  underlying  conditions  are  Cushing’s  syndrome,
pheochromocytoma,  hyperthyroidism,  hyperparathyroidism,  pregnancy,  primary
aldosteronism, obstructive sleep apnea, and coarctation of the aorta etc. Many drugs can
also be a leading factor for secondary hypertension. Adrenal steroids,  Antidepressants,
Appetite  suppressants,  Cocaine,  Cyclosporine,  Erythropoietin,  Nasal  decongestants,
NSAIDs, Oral contraceptives, Sympatho-mimetics are some drugs in above class.
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A.10  Primary  hypertension  can  result  from  multiple  factors  which
includes
1. Abnormalities in rennin-angiotensin-aldosterone-system,natriuretic hormone
2. Pathological  disturbance in nerves  system (in CNS,  nerve fibers  of  autonomic
nerve system , adrenergic or baroreceptors)
3. Abnormalities in renal system or auto regulatory process for sodium excretion,
plasma volume, arteriolar constriction.
4. Either  because  of  increased  production  of  angiotensin  II  and  endothelin  I
(vasoconstrictors) or a decrease in synthesis of vasodilators like - prostacyclin,
bradykinin, and nitric oxide.
5. Sodium intake: increased vascular reactivity and a rise in BP can be resulted from
excessive sodium intake and inhibition of sodium transport.
6. Intracellular calcium concentration: a rise in intracellular calcium concentration
may results  in  alteration  of  vascular  smooth muscle  function and elevation in
peripheral vascular resistance. 
The  life  threatening  events  in  hypertensive  patients  is  mainly  associated  with
cerebrovascular events, CV events and renal failure.   
A.11 TREATMENT
The overall aim of antihypertensive therapy is to reduce morbidity and mortality
associated  with  elevated  blood  pressure18.  A disproportionate  rise  in  systolic  blood
pressure with respect  to diastolic blood pressure is founded in elderly patients due to
decreased compliance of blood vessels associated with aging and atherosclerosis. So it’s
founded that more difficulty is there with systolic pressure reduction than diastolic blood
pressure  reduction.  Systolic  blood  pressure  is  used  as  primary  clinical  marker  in
hypertension, and the same is the better predictor of CV complication. In most of the
population an achievement of blood pressure <140/90 mm Hg is considered as desirable.
It is preferred to be <130/80 mm Hg in subjects with diabetes mellitus, chronic kidney
disease, coronary artery disease (MI, angina) etc. And for patients with LV dysfunction a
blood pressure lower than 120/80 mmHg is advised.
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The  primary  focus  is  given  to  SBP  reduction.  Life  style  modifications,
pharmacological treatment with single drug or combination are required to reduce blood
pressure. And that must be prescribed according to patient condition and the other co-
morbidities present.
A.12 NON PHARMACOLOGICAL THERAPY
Lifestyle  modifications  are  advisable  as  initial  approach  to  pharmacological
treatment.  Epidemiological  data’s  supports  its  importance  in  hypertensive  population.
Minor  alteration  in  normal  physical  activity  and  diet  control  can  reduce  blood
pressure.Non  pharmacological  method  helps  the  patients  to  participate  actively  in
management of disease.   
Body weight reduction19, sodium restriction, increased physical activity, smoking
cessation,  moderate  consumption  of  alcohol  is  the  major  consideration  in  life  style
modification.  
A.12 a) BODY WEIGHT REDUCTION
Obesity  and  hypertension  are  closely  associated  and  have  positive  degree  of
correlation20. Even the exact mechanism is not known with lowering of BP body can be
attain regardless of salt consumption. Secretion of insulin is high in obese population that
may cause an increase in insulin mediated renal tubular reabsorption of Na+ and extra
cellular  volume  expansion21.  A  combination  of  aerobic  exercise  with  good  dietary
consideration is advised in hypertension.
A.12 b) SODIUM RESTRICTION
Restriction of salt intake up to 5g/day offers a significant reduction in pressure
(12/6 mm Hg),the better response is observed in subjects with high blood pressure.When
it  come  to  the  age  consideration  subjects  over  40  years  are  more  responsive  to  the
moderate restriction of salt22. Improved responsiveness to some antihypertensive drug is
an additional benefit of moderate salt intake. Reduced sodium intake to approximately
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100 mmol  /day can  prevent  hypertension.  Lower  intake  of  sodium approximately 60
mmol /day further reduce pressure in both hypertensive and normotensive subjects24.
A.12 c) INCREASED PHYSICAL ACTIVITY
Lack  of  physical  activity  is  highly  correlated  with  hypertension.  The
cardiovascular disease is decreased with increased physical activity25. A regular isotonic
exercise reduces the blood volume and plasma catecholamine’s, with this atrial natriuretic
peptide concentration in plasma is increased26.Regular isotonic exercise offers a reduction
of 10mm hg of blood pressure.  
It also reduced plasma renin activity, norepineprine levels in plasma.
A.12 d) SMOKING CESSATION
Cigarette  smoking  is  one  of  the  strongest  contributors  to  the  risks  of
cardiovascular  diseases,  including  coronary  heart  disease,  stroke,  sudden  death,
peripheral artery disease, and aortic aneurysm27. Considerable reductions in the risk of
cardiovascular  diseases  occur  immediately  after  the  discontinuation  of  cigarette
smoking28.Alterations in blood pressure (BP),  heart rate (HR), and autonomic nervous
function are thought to be at least in part responsible for the rapid reduction in the risk of
cardiovascular diseases after quitting.
A.12 e) MODERATE CONSUMPTION OF ALCOHOL
Consumption of alcohol is restricted in hypertensive population as it can leads to
elevation  in  blood  pressure.  High  alcohol  consumption  leads  to  increased  risk  for
cerebrovascular  accidents.  Not  more  than  30  ml  of  alcohol  per  day  is  advised  to
hypertensive subjects.  
A.12 f) DIET
Diet with  increased usage of  fruits,  vegetables and low-fat  dairy products and
includes whole grains,  nuts, poultry and fish29.  It  has low quantities of fats, red meat,
sweets and sugar-containing beverages. It is thus rich in potassium, magnesium, calcium
Ultra college of pharmacy, Madurai. Page 13
                                                                                                                        INTRODU
CTION
and fiber and has low amounts of total  fat,  saturated fat  and cholesterol is advised in
hypertension30.  Some  example  for  the  above  includes  vegan’s  diet,  dash  diet,
Mediterranean diet31. Animal products meat and it’s product have been shown to rise in
BP, were fish has shown to reduce BP because of omega -3 fatty acid. 
A.13 ORAL ANTIHYPERTENSIVE DRUGS
Drugs that  are  used  to  treat  hypertension  are called  as  antihypertensive
drugs. Antihypertensive  therapy is  meant  to  prevent  the  complications  of  high  blood
pressure,  such  as  stroke, myocardial  Infarction.   Reduction  of  the  blood  pressure  by
5 mmHg can decrease the risk of stroke by 34%, of ischemic heart disease by 21%, and
reduce  the  likelihood  of  dementia,  heart  failure,  and  mortality from  cardiovascular
disease 
A.13a) DIURETICS
These classes of drug are very important in hypertensive treatment. The diuretics
are also known as water pills – as they help body get rid of water and salt through urine.
Diuretics bring out an alteration in Na+ balance and decrease in extra cellular volume.
They are used either alone or in combination with other antihypertensive drugs. Diuretics
are used in treatment of several pathological conditions like high blood pressure, heart
failure, kidney and liver problems and glaucoma etc.
The exact  mechanism for  arterial  blood pressure  reduction by diuretics  is  not
certain .Initially the interaction with thiazide –sensitive Na-cl co transporter in kidney
decreases the extra cellular volume which can produce fall in cardiac output. Reduction
in blood pressure is produced and maintained in long term therapy because of reduced
vascular resistance.
Diuretics are wildly used to treat hypertension. Thiazide diuretics having additive
effect with other antihypertensive drugs, this reason sounds for its combination regimen
with other antihypertensive drugs. Diuretics show an advantage of minimizing the salt
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and water retention that is commonly produced by vasodilators and some sympatholytic
drugs.
  The most commonly used diuretics are hydrochlorothiazide,  furosemide,  and
torsemide. The combination of triamterene and hydrochlorothiazide and metolazone are
also  used  in  antihypertensive  therapy.  Thiazide  diuretics  are  used  in  indication  like
hypertension and to treat edema in heart failure. Loop diuretics are used in subjects with
congestive  heart  failure  symptoms  and  in  emergency  symptoms.  Potassium  sparing
diuretics are mainly suggested in CHF.
Omitting or underutilization of diuretics leads to “resistant hypertension”
A.13 b) SYMPATHOLYTIC AGENTS
 Both α and β adrenergic receptor antagonist drug shows antihypertensive action.
Early invented sympathetic drugs were poorly tolerated and adverse side effects. Many of
new sympathetic drugs  are currently used in antihypertensive therapy.  They primarily
used in treatment of angina pectoris and their arterial blood pressure lowering activity is
latterly investigated. 
Reduction of blood pressure by β adrenergic agents are achieved through different
mechanisms  including,  reduction  in  myocardial  contractility,  heart  rate,  and  cardiac
output. On general consideration blood pressure reduction is produced by blocking action
of adrenaline  receptor.  Beta  blockers  are  prescribed  in  population with  heart  disease,
angina, or history a heart attack. 
Examples: propranolol, metoprolol,atenolol.  
Alpha1 adrenergic  antagonist  drugs  are  used  in  therapy of  hypertension.  They
reduce arteriolar resistance and increase venous capacitance; hence the reduction in blood
pressure  is  obtained.  The  α1 adrenergic  receptor  blockers  are  not  recommended  as
monotherapy for hypertensive patients but suggested to use in combination with diuretics
and  β  blockers.  Enhanced  effect  of  α1 adrenergic  receptor  blocker  is  observed  on
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combining with  β  receptor  antagonist.  Since α1 adrenergic receptor  blocker  improves
urinary symptoms they are attractive drugs for hypertensive patient with benign prostatic
hyperplasia.  
Examples: prazosin, terazosin, doxazosin.
A.13 c) COMBINED α1AND β ADRENERGIC RECEPTOR ANTAGONISTS
The drugs with combined α1  and β adrenergic receptor antagonist action are also
there in anti hypertensive category; they include labetelol, carvedilol etc. In that labetelol
is  given  intravenously  to  reduce  the  blood  pressure  rapidly  so  used  in  treatment  of
hypertensive emergencies. Another drug carvedilol reduces the mortality in patients with
systolic dysfunction and heart failure when used with diuretics and ace inhibitors. 
Centrally acting antihypertensive agents like methyldopa, clonidine, guanfacine
and adrenergic neuron blockers are also comes under the sympatholytic agents. 
A.13 d) CALCIUM CHANNEL BLOCKERS
Calcium Channel  Blockers(CCBs)  are  a  group  of  drugs  used  in  treatment  of
hypertension.  The  antihypertensive  action  is  quick  and  long  acting  preparations  are
available  for  once  a  day  administration.  The  CCBs  monotherapy  is  effective  in  -
50%hypertensive  subjects.  CCBs  voltage  sensitive  calcium  channel  blocking  action
reduces the entry of extracellular calcium into cells cause cardiac and smooth muscle
relaxation. These above change leads to vasodilation and a corresponding reduction in
BP. CCBs blood pressure regulation is independent of patient rennin status. CCBs are
effective  in  lowering  of  blood  pressure  and  decreasing  cardiovascular  events  in  the
elderly with isolated systolic hypertension.
Examples: nifedipine, diltiazem, verapamil, nicardipine, amlodipine, foelodipine. 
A.13  e)  ANGIOTENSIN  CONVERTING  ENZYME  (ACE)
INHIBITORS
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The ACE inhibitors are one of the first choice drugs in all grades of essential as
well  as  renovascular  hypertension. Most patients require relatively lower doses.  Used
alone they control hypertension in patients, and addition o f a diuretic / β blocker extends
efficacy to 90%.  The ACE facilitates production of angiotensin II, which has a major role
in regulating arterial BP. ACE is distributed in many several different cell types including
endothelial cells. The major site for angiotensin II production is the blood vessels. ACE
inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor
and stimulator  of aldosterone secretion.  ACE inhibitors  also block the degradation of
bradykinin  and  stimulate  the  synthesis  of  other  vasodilating  substances  including
prostaglandinE2 and prostacyclin. The fact that ACE inhibitors lower BP in patients with
normal plasma renin activity suggests that bradykinin and perhaps tissue production of
ACE are important in hypertension.
ACE inhibitors widen or  dilate blood vessels to improve the amount of blood
heart pumps and lower blood pressure.ACE inhibitors also increase blood flow, which
helps to decrease the amount of work heart has to do and can help protect the kidneys
from  the  effects  of  hypertension  and  diabetes.  ACE  inhibitors  are  used  in  many
indications  including  high  blood  pressure,  heart  failure,  heart  attack,  and  preventing
kidney damage associated with high blood pressure and diabetes.
Examples: captoril, enalapril, lisinopril, quinapril, ramipril, fosinopril.
A.13 f) ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBs)
ARBs  produce  blood  pressure  reduction  by  antagonizing  the  effects  of
angiotensin II, thus relaxation of smooth muscle is produced which leads to vasodilation,
increase  renal  salt  and  water  excretion,  reduce  plasma  volume  and  decrease  cellular
hypertrophy. The ARBs have the same effects as ACE inhibitors but work by different
mechanism. ARBs also overcomes some disadvantages of ACE inhibitors, which not only
prevents the conversion of angiotensin I to angiotensin II but also prevent the ACE –
mediated degradation of bradykinin. 
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Clinical  trials  comparing  ARBs with  active  controls  have  reported  significant
reductions in stroke in ARB treated patients. Data on ARBs and other drugs that activate
the RAS support a potential role for RAS in protecting against stroke32.
Clinical trials havealso demonstrated that ARBs effecting against in reducing the
risk of CV mortality, stroke, HF, and a new onset atrial fibrillation33. Ongoing trials are
expected  to  confirm and may be extend  the place  of  such  agents  for  improving CV
outcomes34.
The  addition  of  thiazide  diuretic  can  increase  the  efficacy  significantly.ARB
therapy  offers  a  significant  reduction  in  progression  of  nephropathy  in  hypertensive
patients  with  diabetes  and  a  reduction  in  risk  of  CV  events  in  patients  with  LV
dysfunction. ARBtherapy is an alternative to ACE inhibitor therapy in intolerant patients.
ARBs show the lowest incidence of side effects compared with other antihypertensive
drugs.  The ARBS have advantage over  ACE inhibitors  since they didn’t  produce dry
cough.  
. Examples:  losartan, candesartan, lrbesartan, valsartan, telmisartan
A.13 g) VASODILATORS:
The  vasodilators  directly  act  on  arteries  and  with  little  action  on  veins.
Vasodilators  produce  better  reduction  in  diastolic  blood  pressure  than  systolic  blood
pressure.  Vasodilators  are  combined  with  diuretics  and  sympatholytic  agents  for
achieving better therapeutic response. Vasodilators are used in hypertensive crisis and are
administered intravenously to rapid lowering of blood pressure.
Examples:
Arterial: hydralyzine, minoxidil, diazoxide, fenoldopam. 
Arterial and venous: nitroprusside.
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2. DIABETESMELLITUS
The diabetes  mellitus is  a commonest  endocrine  disorder.  This  is  a  chronic
condition and is characterized by hyperglycemia due to impaired insulin secretion with or
without insulin resistance. Diabetes is developed in people when the pancreas does not
produce enough insulin or when the cells in the muscles, liver and fat do not use insulin
properly or due to combination of both of the above reasons.  Due to this the amount of
glucose in the blood increases while the cells are starved of energy. High blood glucose,
also called hyperglycaemia. The most common forms of diabetes are type 1 (10%), which
is  an  autoimmune  disorder  and  type  2  (90%),  which  is  associated  with  obesity.
Gestational diabetes is the form of diabetes occurring during pregnancy. Other forms of
diabetes are rare and are caused by a single gene mutation.
It is a metabolic disorder which is characterized by chronic hyperglycemia with
disturbances  in  carbohydrate,  fat  and  protein  metabolism  resulting  due  to  defects  in
insulin secretion, insulin action or both.
2.1 DEFINITION
Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia
and abnormalities in carbohydrate, fat, and protein metabolism.It results from defects in
insulin secretion, insulin sensitivity, orboth. Chronic microvascular, macrovascular, and
neuropathic complicationsmay ensue.
2.2 CLASSIFICATION OF DIABETES MELLITUS: 
Out of many types, the most common ones are35
1. Type 1 Diabetes Mellitus 
• Immune Mediated
• Idiopathic
2. Type 2 Diabetes Mellitus 
3. Other specific types of diabetes 
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• Genetic defects of islet β-cell function
• Genetic defects of insulin action
• Diseases of the exocrine pancreas
• Endocrinopathies.
• Drug-or chemical-induced diabetes
• Other genetic syndromes 
2.3 EPIDEMIOLOGY
In  2000, according to the WHO, at  least 171 million people worldwide suffer
from  diabetes  which  is  about  2.8%  of  the  population.  The  incidence  of  diabetes  is
increasing rapidly. By 2030 it is estimated that this number will almost double. Diabetes
mellitus occurs throughout the world, but it is more common (especially type 2) in the
developed countries. The greatest increase in incidence is, expected to occur in Asia and
in Africa, where most patients will probably be found by 2030. The increase in incidence
of  diabetes  in  developing  countries  is  due  to  the  trend  of  urbanization  and  lifestyle
changes, perhaps most importantly due to their ‘Western-style’ diet. 
Diabetes mellitus prevalence is expected to increase with age and the number of
older persons with diabetes is expected to increase as the number of elderly population
increases. Type 1 diabetes accounts for 5-10% of cases that affects 1 of 400 children and
adolescents. Type 2 diabetes accounts for about 90-95% of all cases of diabetes and is
relatively common. It can go undiagnosed for many years. But the number of cases that
are being diagnosed is also rising rapidly and that leads to reports of a diabetes epidemic.
2.4 DIAGNOSIS OF DIABETES MELLITUS
Ultra college of pharmacy, Madurai. Page 20
                                                                                                                        INTRODU
CTION
Diagnosis of diabetes is done by measuring blood/plasma glucose level36.
• Fasting plasma glucose (FPG). 
• Oral Glucose Tolerance Test (OGTT).
• 2 Hour Post Prandial Plasma Glucose Level (2HPG).
• Glycosylated  Haemoglobin (HbA1C):
2.4 PATHOPHYSIOLOGY
2.4 a) PATHOPHYSIOLOGY OF TYPE 1 DIABETES/IDDM:
It  is  characterized  by  absolute  insulin  deficiency  either  through  autoimmune
attack on pancreas,  a viral  infection or is  idiopathic.  As a result  cells in the islets of
Langerhans in the pancreas are destroyed resulting in hypoinsulinaemia. The cause of
type 1 diabetes is still  not fully understood but it  is believed to be of immunological
origin. 
2.4 b) PATHOPHYSIOLOGY OF TYPE 2 DIABETES
          The two metabolic defects that characterize type 2 diabetes are
1. The derangement in β-cell secretion of insulin
2. The inability of the peripheral tissues to respond to insulin.
2.5 TREATMENT:
 The two main goals of treatment are37:
1. Reduction  of  mortality  and  concomitant  morbidity  due  to  assorted  diabetic
complications.
2. Preservation of quality of life.
2.5 a) NON PHARMACOLOGICAL TREATMENT OR DIABETES
           Life style modifications are the cornerstone of management of diabetes of diabetes
mellitus and include the prescription of a healthy diet, regular exercise, the management
of stress, and avoidance of tobacco.
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2.5 b) PHARMACOLOGICAL TREATMENT
1. BIGUANIDES: Metformin.
2. THIAZOLIDINEDIONES:Pioglitazone ,Rosiglitazone.
3. SULFONYLUREAS:First-generation:-Tolbutamide,Chlolrpropamide.
Second-generation:-Glipizide,Glibenclamide,Glimepiride,
Glicazide
4. MEGLITINIDES:Repaglinide and Nateglinide38.
5. ALPHA GLUCOSIDASE INHIBITORS:Acarbose, Miglitol and Voglibose
.
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P.R. Anandvijayakumar  et al.,39(2013) conducted a study on the pleiotropic effects of
Telmisartan  and  Olmesartan  in  hypertensive  patients  with  metabolic
syndrome.Telmisartan20mg/day and Olmesartan 10mg/day were administered to group A
& B respectively for two months. The blood pressure, lipid profile (TC, TGL, LDL and
HDL&VLDL)& FBS were measured on baseline and at the end of study. Both of the
study  drugs  demonstrate  the  significant  reduction  in  blood  pressure,  FBS,  LDL and
VLDL. And telmisartan is considered as an ideal agent in patients with elevated lipid
profile because of its significant increase (p<0.05) in the levels of HDL after two months
of treatment. The pleiotropic effects of Telmisartan showed within two months of study
recommend the use of the drug in metabolic syndrome patients. 
Yuji Shimizu et al.,40(2012)has studied  the metabolic effect of combined Telmisartan
and Nifedipine therapy in patients with essential hypertension. The Patients were initiated
on Telmisartan (40 mg/day). If their office BP was not reduced to 140/90 mmHg after 6
weeks, Nifedipine(20–40 mg per day) was added for 18 weeks. In the study Telmisartan
showed  a  reduction  in  blood  pressure  and  (HOMA-IR),  but  didn’t  reduced  the
adiponectin  or  leptin  levels.  Telmisartan  sounds  for  favorable  metabolic  effect  in
hypertensive patients without preexisting metabolic disorders.
Naziayasmeen  et  al.,41(2011) has  conducted  a  study  on  efficacy  and  tolerability  of
different antihypertensive drugs in patients withessential hypertension. Drugs used were
Atenolol (A) 50mg, Enalapril(E)5mg, Nifedipine (N)10mg and Furosemide (F) 40mg in
monotherapy (n=86) and in 2 and 3 drugs combination (n=166). After 8 weeks oftherapy
patients were assessed for efficacy and tolerability. In the study highest decrease in SBP
was seen with A+E+N combination (29.2%) and in DBP with N+F combination (17.7%).
All the drug groups from monotherapy and combination therapy reduced BP effectively.
Mosteffective groups were A+E+N and N+F combination. Enalapril was effective and
mostfrequently used drug. 
SE Kjeldsen et al;42(2010) has studied the Effects of Losartan vs Candesartan inreducing
cardiovascular events in theprimary treatment of hypertension. There was no difference
in blood pressurereduction when comparing the Losartan and Candesartangroups during
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follow-up.  Compared  with  the  Losartangroup,  the  Candesartan  group  had  a  lower
adjusted hazardratio for total CVD, Heart failure, Cardiac arrhythmias, and Peripheral
artery disease. The observations of study suggesting that, since there is no difference in
blood pressure reduction then thedivergent clinical outcomes are due to difference in the
pharmacological properties of thedrugs.
R.M Nixon  et  al.,43 (2009)Conducted  a  study on  Valsartan  VS other  angiotensin  II
receptor blockers in the treatment of hypertension .Six studies include trial arms with
Candesartan,  Six  Irbesartan,13  Losartan,  two  Olmesartan,  five  Telmisartan  and  12
Valsartan. The study reported change in systolic and diastolic blood pressure from base
line to follow upping 12 weeks    The weighted average reduction in mean SBP and DBP
for Valsartan 160 mg 15.32/11.3 mmHg and for Valsartan 320 mg was 15.85/11.97mm
Hg; these are statistically significantly greater reduction compared with Losartan 100 mg,
which was 12.01mm Hg and 9.37mm Hg for  SBP and DBP respectively.  This paper
shows that Valsartan at doses of 160 mg or 320 mg is more effective at lowering blood
pressure than Losartan 100 mg. For other ARBs at comparable doses, valsartan achieves
comparable antihypertensive efficacy. 
Paolo verdecchia et al.,44(2009)conducted a study named -  “Comparative assessment of
angiotensin receptor blockers in different clinical settings”. The primary outcome was the
time to onset of diabetic nephropathy, defined by persistent albuminuria. The primary
endpoint  was  achieved  by  14.9%  of  patients  with  placebo,  9.7%  of  patients  with
Irbesartan 150 mg (P = 0.08) and 5.2% of patients with Irbesartan 300 mg (P = 0.001).
These  effects  were  independent  of  BP  changes.  The  overall  message  of  the  trials
examined  in  this  review  is  that  intervention  with  ARBs  at  different  steps  of  the
cardiovascular  disease  continuum  is  effective  to  slow  down  or  block  the  disease
progression,  with  consequent  measurable  benefits.  The  study  results  show  that,
Telmisartan reduced cardiovascular events in a broad population of patients with high
cardiovascular  risk,  with  a  protective  effect  similar  to  the  ACE-inhibitor  comparator
Ramipril. Losartan was superior to the beta-blocker atenolol in reducing the risk of stroke
in patients with hypertension and LV hypertrophy. In patients with type 2 diabetes and
nephropathy,  Losartan in addition to conventional  therapy reduced protenuria and the
Ultra College Of pharmacy, Madurai. Page 23
                                                                            REVIEW OF LITERATURE
progression to end stage renal disease. In patients with chronic heart failure, Losartan
proved to be an alternative therapeutic option in patients intolerant to ACE-inhibitors.
Shiho nakayama et  al.,45(2008)studied the effects of  Olmesartan and Telmisartan on
Blood  Pressure  and  metabolic  Parameters  in  Early-Stage  Type-2  Diabetics  with
Hypertension, in this open-label prospective crossover study, theycompared the effects of
Olmesartan (20 mg/day) and Telmisartan (40 mg/day). They analyzed the blood pressure
lowering effects of each drug by 24-h ambulatory blood pressure monitoring at 0, 8, and
16  weeks,  and  metabolic  parameters  and  inflammation  markers.  Olmesartan  lowered
mean systolic and diastolic blood pressure more significantly than Telmisartan.  While
there were no differences between the groups in metabolic parameters.
Derosa et al.,46(2007)studied the metabolic effects of Telmisartan and Irbesartan in type 2
diabetic patients with metabolic syndrome treated with Rosiglitazone. Evaluation were
done on mass index, glycosylated haemoglobin, fasting plasma glucose, fasting plasma
insulin, homeostasis model assessment-index, total cholesterol , low density lipoprotein ,
high density lipoprotein-cholesterol, triglycerides, systolic blood pressure, diastolic blood
pressure,  adiponectin and resistin during 12 months of  this treatment.In  addition to a
comparable antihypertensive effect for Telmisartan and Irbesartan after 6 and 12 months,
both  treatments  were  associated  with  a  significant  reduction  in  TC and  LDL plasma
levels compared with baseline. After 6 months of treatment, only the telmisartan group
experienced a significant  improvement in (HbA(1c)), FPG, Homa-IR, adiponectin and
resistin compared with the baseline values, whereas both drug regimens were associated
with  a  significant  improvement  in  these  parameters  after  12  months.  However,  the
improvements observed in the Telmisartan group were significantly larger than that noted
in the Irbesartan group. FPI significantly decreased only after 12 months of treatment in
both groups, but again, the reduction was significantly larger in the Telmisartan-treated
subjects.  Telmisartan  seemed  to  improve  glycaemic  and  lipid  control  and  metabolic
parameters of the metabolic syndrome better than irbesartan.
Nagel et al.,47 (2006) compared Telmisartan 40 mg versus placebo in 20 individuals with
insulin resistance (homeostatic model assessment [HOMA] index >2.3) and abdominal
obesity (body mass index [BMI] >25 kg/m2 and waist circumference >95 cm in males or
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80  cm in  females)  in  a  randomized,  crossover  trial  lasting  12  weeks.  Compared  to
placebo, Telmisartan promoted a significant reduction in the glucose area under the curve
(AUC) during an oral glucose tolerance test (11%;p = .04). Non significant changes in the
HOMA index (11% reduction;p = .06) and adiponectin  (6%;p = increas.09)  were also
present during telmisartan treatment.
R Asmar et al.,48 (2005) -conducted a study on effectiveness of angiotensin receptor
blockers in blood pressure control. Variation in blood pressure with individual ARBs are
taken into comparison in the study. The study drugs included were Losartan, Irbesartan,
Candesartan,  Telmisartan,  and Olmesartan. Several  newer ARBshave been reported to
provide  equivalent  antihypertensive  efficacy to  Amlodipine  and  greater  efficacy than
Losartan,  Valsartan  or  both.  Secondly,  increases  in  dose  may  improve  the
antihypertensive  efficacy  of  agents  such  as  Valsartan,  although  clinical  studies  are
necessary to provide characterization of new, higher-dose monotherapy.  Thirdly,  fixed
dose combinations with hydrochlorothiazide (HCTZ) increase the antihypertensive effect
of all ARBs.
Vitale et al., 49(2005)conducted a study on metabolic effect of Telmisartan and Losartan
in  hypertensive  patients  with  metabolic  syndrome.  At  baseline  and  end  of  treatment
fasting and post pradinal plasma glucose, lipid profile, insulin sensitivity, and systolic and
diastolic pressures were determined.After 3 months' treatment, Telmisartan reduced 24-
hour mean SBP and DBP significantly more than Losartan.  There was no significant
correlation between the decrease in blood pressure and the change in FPG (p = 0.020) or
FPI (p = 0.012).Both Telmisartan and Losartan were well tolerated.On comparison it is
founded that the Telmisartan but not Losartan, significantly (p<0.05) reduce free plasma
glucose. The results of this study explains as well as providing superior blood pressure
control, Telmisartan unlike, Losartan, displayed insulin sensitizing activity.
DerosaG et al.,50(2004) has studied the effects of Telmisartan compared with Eprosartan
on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2
diabetic  patients.  Evaluated  the  antihypertensive  activity,  glucose  homeostasis  and
plasma lipid profile. Compared with baseline, a significant reduction (p<0.01) in seated
trough systolic blood pressure (SBP) was detected after 12-month treatment with either
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Telmisartan or Eprosartan. The antihypertensive effect of Telmisartan was significantly
superior (p<0.05). No change in body mass index or glucose metabolism was observed
with  either  active  treatment,  or  with  placebo.  Telmisartan,  but  not  Eprosartan,
significantly  improved  plasma  total  cholesterol  (p<0.01),  low-density  lipoprotein
cholesterol (p<0.01) and triglycerides (p<0.05) compared with Eprosartan. The 12-month
Telmisartan treatment produced a significantly greater reduction in DBP than Eprosartan
and significantly improved plasma lipids.
Michael  schupp  et  al.,51(2004)  -  has  studied,angiotensin  Type  1  Receptor  Blockers
Induce Peroxisome Proliferator–Activated Receptor-γ Activity.The findings of the study
sounds that, ARB Losartan enhanced aP2 expression only at high concentrations, whereas
Eprosartan had no significant effects, Irbesartan and Telmisartan (10 µmol/L) markedly
induced  transcriptional  activity  of  PPARγ.  Irbesartan  and  Telmisartan  also  induced
PPARγ activity in an AT1R-deficient cell model, demonstrating that these ARBs stimulate
PPARγ activity independent of their AT1R blocking actions. The study demonstrates that
a specific subset of ARBs induces PPARγ activity, thereby promoting PPARγ-dependent
differentiation  in  adipocytes.  The  activation  of  PPARγ  demonstrates  new  pleiotropic
actions of certain ARBs, providing a potential mechanism for their antidiabetic effects.
UjalaVerma et al.,52 (2004)did a study on Antihypertensive Efficacy of Carvedilol and
Amlodipine in patients of mild to moderate hypertension . Blood pressure was recorded
in the sitting and standing position during followup visits at 2,4,8 and 12 weeks. Dosage
adjustments  if  neededwere  made  at  4  and  8  weeks  of  study.  Both  Carvedilol  and
Amlodipine produced a statisticallysignificant (P<0.001) and dose related fall in SBP and
DBP.  On  comparative  analysis  of  the  effect  of  Carvedilol  andAmlodipine  on  BP,
Amlodipine produced a greater  fall  in  sitting and standing SBP at  all  study intervals
ascompared to carvedilol, with statistically significant fall at 8 and 12 weeks (P<0.01).
The findings of the study indicate that Carvedilol has become an alternative treatment for
mild to moderate hypertension.
Daholf B et al.,53(2002) conducted a study on cardiovascular morbidity and mortality in
the  Losartan.LVH  ascertained  by  electrocardiography  (ECG).They  observed  out  that
blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the
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Losartan and Atenolol groups, respectively. New-onset diabetes was less frequent with
Losartan. Interpretation Losartan prevents more cardiovascular morbidity and death than
atenolol for a similar reduction in blood pressure and is better tolerated. Losartan seems
to confer benefits beyond reduction in blood pressure.
Lerch  M et  al.,54(1998) studied  the effects  of  angiotensin  II-receptor  blockade  with
losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of
hypertensive parents. Insulin sensitivity index (SI), determined by the Minimal Model
Method of Bergman, fasting plasma insulin and glucose concentrations, serum total and
HDL cholesterol, serum triglycerides, and plasma ET-1 levels were assessed. Compared
with placebo,  Losartan administration did not significantly modify SI,  fasting plasma
insulin  and glucose.  Plasma ET-1 levels  also did not differ  significantly between  the
placebo and Losartan serum total  cholesterol  and triglycerides  decreased significantly
with losartan treatment. Body weight, BMI, heart rate (HR), blood pressure (BP), and 24-
h urinary sodium, potassium, and creatinine values were stable throughout  the study.
These findings demonstrate that Losartan 50 mg daily, does not alter insulin sensitivity
and ET-1 in normotensive offspring of essential hypertensive parents.the study shows that
the Losartan significantly reduced serum total cholesterol and total triglyceride levels.
Pedro Luis de Pablosvelasco et al.,  55(1998) has studied the effects of Losartan and
Diltiazem on Blood Pressure, Insulin Sensitivity, Lipid Profile and Microalbuminuria in
Hypertensive Type 2 Diabetic Patients. At baseline and after 3 months, plasma glucose,
glycated  haemoglobin,  uric  acid,  lipid  profile,  albumin  excretion  rate  and  creatinine
clearance,  Insulin  sensitivity  was  estimated  by  an  insulin  suppression  test,  and
ambulatory blood pressure was monitored for 24 hours.  Differences between the two
treatments were not significant. Insulin sensitivity and lipid profile were not modified by
any  of  the  treatments  and  no  adverse  effects  were  reported. Both  drugs  were  well
tolerated and effectively reduced blood pressure and albuminuria,  but  did not modify
insulin sensitivity or lipid profile.
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3. DRUG PROFILE
3.1 LOSARTAN POTASSIUM
NAME:  Losartan potassium
BRAND NAMES: cozaar
DESCRIPTION56: 
Losartan  potassium  is  an  Antihypertensive  drug  belongs  to  the  class  ARB
(Angiotensin receptor II antagonist). Losartan potassium is a non peptide molecule shows
high  affinity  to  the  Angiotensin  receptor  II,  and  the  drug  inhibits  the  action  of  the
angiotensin receptor II on vascular smooth muscles. As the result of inhibitory action a
reduction in blood pressure is obtained.
CHEMICAL IUPAC NAME:
Mono potassium salt of 4-butyl-4chloro-1-[[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-
4-yl]methyl]-1H-imidazole -5-methanol.
CHEMICAL FORMULA: C22H22ClKN6O
CHEMICAL STRUCTURE:
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MOLECULAR WEIGHT: 461.0 Daltons
STATE: White to off-white crystalline powder
MELTING POINT: 461.010 C
THERAPEUTIC CATEGORY:
Antihypertensive (Angiotensin receptor II antagonist)
PHARMACOLOGY:
Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin
converting  enzyme  (ACE,  kininase  II)],  is  a  potent  vasoconstrictor,  the  primary
vasoactive hormone of the renin-angiotensin system and an important component in the
pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal
cortex.  Losartan  and  its  principal  active  metabolite  block  the  vasoconstrictor  and
aldosterone-secreting  effects  of  angiotensin  II  by selectively blocking  the  binding of
angiotensin II to the AT1 receptor.
MECHANISM OF ACTION: 
Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin
converting  enzyme  (ACE,  kininase II)],  is  a  potent  vasoconstrictor,  the  primary
vasoactive hormone of the renin-angiotensin system and an important component in the
pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal
cortex.  Losartan  and  its  principal  active  metabolite  block  the  vasoconstrictor  and
aldosterone-secreting  effects  of  angiotensin II  by  selectively  blocking  the  binding  of
angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle,
adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to
be associated with  cardiovascular  homeostasis.  Both Losartan and its  principal  active
metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much
greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. Neither
Losartan nor its active metabolite inhibits ACE (kininase II,  the enzyme that  converts
angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block
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other  hormone  receptors  or  ion  channels  known  to  be  important  in  cardiovascular
regulation.
DOSAGE FORM: 
Form: Tablet
Route:  Oral
PHARMACOKINETICS:
ABSORPTION:
The  drug  is  well  absorbed.  Administration  along  with  food  shows  a  slight
decrease in absorption and it has only minor effect on losartan or active metabolite AUC.
Systemic bioavailability of losartan is about 33%.
DISTRIBUTION:
Volume of distribution is 34 L(losartan) and 12 L (metabolite) 
PROTEIN BINDING:
Losartan  and  active  metabolite  are  highly  binds  to  plasma  protein,  primarily
albumin.  Neither  Losartan nor  metabolite  accumulates  in  plasma upon repeated daily
dosing.
METABOLISM:
Losartan undergoes substantial first – pass metabolism by CYP-450 2CP and 3A4
enzymes.  Fourteen  percent  of  an  oral  dose is  converted  to  an  active  carboxylic  acid
metabolite that is responsible for most of the angiotensin II receptor antagonist activity.
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ELIMINATION: 
The t1/2  of Losartan 2 hr and that of metabolite is 6 to 9 hr. Renal clearance of
Losartan is 75 ml/min and that of metabolite is 25 ml/ min. Biliary excretion contributes
to the elimination of Losartan and metabolite. About 4% is excreted unchanged in the
urine and 6% excreted as active metabolite in metabolite in urine.
INDICATION:
The drug is used alone or in combination with other classes of antihypertensive
drugs.  It  is  used  in  treatment  of  hypertension,  diabetic  nephropathy  in  hypertensive
patients with type 2 diabetes mellitus; reduce risk of stroke in patients with hypertension
and left ventricular hypertrophy.
CONTRAINDICATION:Losartan potassium tablets are contraindicated in patients who
are hypersensitive to any components of this product.
INTRACTION:
Drug – Drug:
Fluconazole: Fluconazole elevates plasma level of Losartan, which will leads to
increase the antihypertensive and adverse effects.
Indomethacin: The antihypertensive effect of Losartan may be blunted. 
Rifamycins: Rifamycins like Rifampin reduces plasma levels of Losartan thus
antihypertensive effects of Losartan got reduced.
Drug and lifestyle:
Alcohol use: It enhances the hypotensive effects of the drug. Avoid use of alcohol
and drug together.
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ADVERSE REACTION: 
The adverse drug reactions Losartan potassium includes, hypotension, orthostatic
hypotension, CNS side effects, GI side effects, UTI Infection, hypersensitivity reaction.
SPECIAL POPULATION: 
Close monitoring must be practiced in patients with hepatic impairment,  renal
impairment .During the pregnancy Losartan is suggested to be stopped. 
Pregnancy: 
When used in pregnancy during the second and third  trimester,  drugs  that  act
directly on renin angiotensin system can cause injury and even death to the developing
fetus. When pregnancy is detected, discontinue therapy as soon as possible. 
Children:
Safety and efficacy not established in hypertensive patients younger than 6 yr of
age or in children’s.
Renal function:
Use caution in treating patients whose renal function may depend on the rennin-
angiotensin – aldosterone system.
Hepatic function:
A lower starting dose is recommended for patients with hepatic impairment.
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3.2Telmisartan
NAME: Telmisartan
BRAND NAMES: Micardis, Tazloc, Telday
DESCRIPTION57:
Telmisartan is  an antihypertensive drug belongs to the class ARB (angiotensin
receptor II antagonist). Telmisartan shows high affinity to the angiotensin receptor II, and
the drug inhibit the action of the angiotensin II on vascular smooth muscles. As the result
of inhibitory action a reduction in blood pressure is obtained .As per the suggestions of
recent studies,  Telmisartan also having beneficial  metabolic effects because of PPAR-
gamma agonistic action.
CHEMICAL IUPAC NAME:
  4′ - [1(1, 4′ - Dimethyl - 2′ - propyl [2, 6′ - bi - 1H - benzimidazol] - 1′ - yl) methyl] - 
[1,1′ - biphenyl] - 2 - carboxylic acid
CHEMICAL FORMULA: C33H30N4O2
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CHEMICAL STRUCTURE:
MOLECULAR WEIGHT: 514.6169 Daltons 
STATE: White solid
MELTING POINT: 261-2630C
THERAPEUTIC CATEGORY: 
Antihypertensive (Angiotensin receptor II antagonist)
PHARMACOLOGY:
Telmisartan is a non peptide molecule, which orally active. It  selectively binds
and  inhibits  the  angiotensin II  AT1receptor  subtype.  Telmisartan  shows much greater
affinity (> 3,000 fold) for the AT1 receptor than for the AT2 receptor. Angiotensin II is the
principle factor of rennin angiotensin system. Telmisartan inhibitory action brings out the
desirable effects like relaxation of smooth muscle thereby vasodilation,increased renal
excretion of salt and water and reduced plasma volume. Telmisartan also have beneficial
metabolic effects because of PPAR-gamma agonistic action.  PPAR-gamma is a nuclear
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receptor related to the insulin sensitizing effect,  PPAR-gamma agonistic action improve
insulin sensitivity and lipid profile in patients with metabolic syndrome.
MECHANISM OF ACTION: 
Telmisartan  binds  with  the  angiotensin  II  ATI  receptor  in  adrenal  gland  and
vascular  smooth  muscle,  mode  of  binding  is  selective  and  reversible.  The  systemic
vascular resistance is produced by the blockade of the angiotensin II. The angiotensin II
is a vasoconstrictor which produces elevation in blood pressure. Telmisartan is a selective
antagonist of angiotensin II receptor because it doesn’t inhibit the angiotensin converting
enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan
having partial agonist  activity towards PPAR gamma. PPAR gamma is an established
target  for antidiabetic drugs.  This sounds that  telmisartan can improves  carbohydrate,
lipid metabolism and controls insulin resistance. 
DOSAGE FORM: 
FORM: Tablet
ROUTE: Oral
PHARMACOKINETICS:
ABSORPTION:
The bioavailability of drug depends on dosage. Administration of telmisartan with
food  shows  a  6%  decrease  in  bioavailability.  Peak  plasma  concentration  generally
reached at 0.5 – 1 hour following oral administration. 
DISTRIBUTION:
Volume of distribution is 500 L 
PROTEIN BINDING:
Protein binding is > 99.5%, principally albumin and α1- acid glycoprotein.
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METABOLISM:
Metabolized  in  liver,  conjugated  into  inactive  acylglucuronide  it  has  been
identified in human plasma and urine.
ELIMINATION: 
When administered orally duration of action is 24 hours. The drug is excreted
unchanged in the feces via biliary excretion mainly; small amount of drug is eliminated
through urine.   
INDICATION:
The drug is used alone or in combination with other classes of antihypertensive
drugs.  It  is  used  in  treatment  of  hypertension,  diabetic  nephropathy  in  hypertensive
patients with type 2 diabetes mellitus,  and in congestive heart  failure population who
can’t tolerate ACE inhibitors.   
CONTRAINDICATION: 
Drug is contraindicated in pregnancy and in patients who hypersensitive to drugs
and  its  components.  Cautious  usage  is  suggested  in  patients  with  biliary  obstruction
disorders,  renal  or  hepatic  insufficiency  and  in  those  with  an  activated  rennin  –
angiotensin system. 
INTRACTION:
Drug – Drug:
Digoxin:
Telmisartan  increases  digoxin  plasma  levels.  Digoxin  levels  must  be
monitored closely.
Warfarin: 
Telmisartan  decreases  the  plasma  warfarin  level,  patient  must  be
monitored closely. 
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Drug and lifestyle:
Alcohol use: It enhances the hypotensive effects of the drug. Avoid use of
alcohol and drug together.
ADVERSE REACTION: 
Upper respiratory tract infection, sinusitis, pharyngitis, back pain, diarrhoea. 
SPECIAL POPULATION: 
Close monitoring must be practiced in patients with hepatic impairment,  renal
impairment. Drug must not be used in pregnancy and lactation.
Pregnant patients:
Use of drug is contraindicated during pregnancy because of potential risk of fetal
and neonatal morbidity and death.
Breast feeding patients:
Assess  risks  and  benefits  before  continuing  drug  in  breast  feeding
women.Because it is not known telmisartan is secreted in human milk.
Pediatric patients:
Safety and efficacy in children have not been established.
Geriatric patients:
No significant difference has been reported compared to younger patients.
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4. AIM AND OBJECTIVES
SCOPE OF THE STUDY
Hypertension is currently affects, approximately one billion adults globally. It is a major
risk factor for cardiovascular diseases (CV) and stroke. The high prevalence of hypertension has
contributed to the present pandemic of CV disease, which now accounts for 30% of all deaths
worldwide. 
 As  the  population  ages  and  the  prevalence  of  contributing  factors  such  as  obesity,
sedentary lifestyle and smoking rise, this figure is projected to increase by 60% to 1.56 billion by
the year 2025. 
 The risk of hypertension increases with age and is associated with gender and ethnicity.
The morbidity and mortality associated with uncontrolled hypertension result in a substantial
economic  burden  as  a  result  of  drug  costs,  hospitalizations,  surgery  and  other  healthcare
resources.  This  cost  is  compounded  by the  humanistic  burden  and  effect  on  quality  of  life
associated with lifestyle modifying adverse events.
 Angiotensin receptor  blockers  (ARBs)  have  become established  as  a  major  class  of
antihypertensive  on  the  basis  of  their  powerful  effects  on  blood  pressure  (BP),  excellent
tolerability  and  pleiotropic  end-organ-protective  effects.  However,  individual  ARBs  vary  in
antihypertensive efficacy, which may be important to clinical outcome. It is well established that
achieving ambitious  BP targets  improves  long-term clinical  outcomes in  the  management  of
hypertension
The present study was to compare the efficacy of Losartan potassium and Telmisartan,
both are belongs to the above mentioned class of angiotensin receptor blockers (ARBs). Of the
above Losartan potassium is the prototype and Telmisartan is a newly introduced ARB.   
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AIM:
• The aim of the present study was to compare the efficacy of Losartan potassium 50 mg
Vs Telmisartan 40 mg in patients with hypertension.
OBJECTIVE:
PRIMARY
• To compare the efficacy of  Losartan potassium 50 mg Vs Telmisartan 40 mg 
• To  assess  the  mean  change  in  Systolic  Blood  Pressure  (SBP)  and  Diastolic  Blood
Pressure (DBP) with Losartan potassium and Telmisartan in a treatment period of three
months.
SECONDARY
• To assess the mean change in Fasting Blood Sugar (FBS) and Post Pradinal Blood Sugar
(PPBS).
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5.  PLAN OF WORK
The present dissertation work was planned to conduct a comparative study on efficacy of
losartan versus telmisartan in hypertensive patients. The study conducted at Manohar Hospital,
Calicut, Kerala.
The Plan of Work Includes:
i. Submission of the protocol for getting the approval from ethical committee.
ii. To get the consent letter from patient.
iii.  Select hypertensive patients for the study.
iv. To design a data collection form.
v. Select monitoring parameters.
vi.  Patients divided into two groups A & B.
vii.  Each group containing 30 patients.
viii.  Prescribing drug for group A: Losartan potassium 50 mg. 
ix.  Prescribing drug for group B: Telmisartan 40 mg.
x.  Checking of SBP&DBP, FBS&PPBS on specified visit. 
xi. Carrying out statistical analysis and recorded.
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STUDY SITE :  Manohar hospital, (170 bedded), Calicut- Kerala.
STUDY DESIGN :  Prospective observational study.
DURATION OF STUDY :  3 months.
DOSAGE :  Losartan potassium 50 mg.
:  Telmisartan 40 mg.
• A total of 60 patients were enrolled in the treatment program.
• A prospective and observational study was carried out to compare efficacy of losartan 
potassium versus telmisartan 40 mg in patients with hypertension. 
• The selected patients were divided into two groups. Group A, group B.
•  Group A (30 patients) were to be treated with Losartan potassium 50 mg.
•  Group B (30 patients) were to be treated with Telmisartan 40 mg.  
STUDY CRITERIA 
Inclusion criteria
 Patients aged between 30 -59 years.
 Patient’s who having sustained diastolic blood pressure >90 mm Hg accompanied by 
elevated systolic blood pressure > 140 mm Hg.
 Patient’s who agreed with prescribed consent form.
Exclusion criteria
• Patient with secondary hyper tension.
• Patient who having other medication with known effects on blood pressure.
• Patient who refuse to participate in study or withdrawing prescribed consent.
• Pregnant and lactating women.
PARAMETERS
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Primary parameters 
• Systolic blood pressure.
• Diastolic blood pressure.
• FBS.
• PPBS.
Secondary parameters 
• Height.
• Weight.
• BMI.
STASTSTICAL ANALYSIS:
The information collected regarding all the selected cases were recorded in a Master Chart.
Data analysis was done with the help of computer (Microsoft exel 2007)
Using this software range, frequencies, percentages, means, standard deviations, and 'p'
values  were  calculated.  The  Students  T  test  was  used  to  test  the  significant  difference  of
quantitative variables,  chi  squre test  was used to test  the significant  difference of qualitative
variables. A 'p' value less than 0.05 is taken to denote significant relationship.
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7. Observations and results
The work entitled comparative study of efficacy of Losartan potassium 50 mg versus
Telmisartan  40  mg in  patients  with  hypertension was  carried  out  in  Department  of  General
Medicine at Manohar hospital, Calicut, kerala. A total number of 60 patients were enrolled in this
study. These patients were divided into two groups (A&B). Group A (30 patients) were treated
with Losartan potassium 50 mg and Group B(30 patients)Telmisartan 40 mg.   
All  primary and secondary parameters  were  recorded  in  the  initial  visit,  systolic  and
diastolic blood pressure recorded at each follow up of 15 days interval and the FBS and PPBS
and weight were recorded at the end of the study.  All the recorded parameters were compared to
assess the efficacy.
Group A: Losartan potassium 50 mg
Group B: Telmisartan 40 mg 
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A. CHARECTERISTICS OF CASES STUDIED 
Table 3: Age distribution 
Age group
(in years )
Group A Group B
No % No %
30 – 39 years 3 10 2 6.67
40 – 49 years 11 36.66 12 40
50 – 60 years 16 53.34 16 53.33
Total 30 100 30 100
Range 38 - 59 30 – 60
Mean 50.17 50.47
SD 6.62 6.25
Out of 60 patients, 30 patients were of group A, out of these 3 patients (10%) between the
age group of 30-39 years,11 patients (36.66%) between the age group of 40-49 years, 16 patients
(53.34%) between the age group of 50-60 years.
Out of 60 patients, 30 patients were of group B, out of these 2 patients (6.67%) between
the age group of  30-39 years,  12 patients  (40%) between the age  group of  40-49 years,  16
patients (53.33%) between the age group of 50-60 years.
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Age distribution
   
     Fig,no 1
The mean age of group A was 50.17± 6.62 years and group B was 50.47 ± 6.25 years. 
Ultra College of Pharmacy, Madurai. Page 45
OBSERVATIONS AND RESULTS
Table 4: Sex distribution 
Sex
Group A Group B
No % No %
Male 18 60 20 66.67
Female 12 40 10 33.34
Total 30 100 30 100
A total of 60 patients were screened and randomized into two treatment group. Out of
which 30 patients were of GROUP A, 18 patients (60%) were males, 12 patients (40%) were
females. In case of GROUP B, 20, patients (66.67%) were males, 10 patients (33.34%) were
females.
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Sex distribution 
Fig,no 2
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Table 5: Physiological parameters
Variable Group A Group B ‘p’ value
Mean SD Mean SD
Weight (in kg) 74.1 5.97 70.57 5.84
Height (in cm) 163.77 6.32 161.77 6.95
BMI 27.64 1.73 26.99 1.92 0.1767
The average weights of patients were 74.1±5.97 in GROUP A and 70.57±5.84 in GROUP
B. The average height of patients was 163.77 ±6.32 in GROUP A and 161.77±6.95 in GROUP B.
The average BMI of patients were 27.64±1.73 in GROUP A and 26.99±1.92 in GROUP B. 
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Physiological parameters
 ±
      Fig,no 3
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Table 6:  Change in BMI
BMI GROUP A GROUP B
First 
visit
Final
value
Difference First 
visit
Final
value
Difference
MEAN 27.64 26.58 1.05 26.99 25.91 1.08
SD ± 1.73 ± 1.75 ± 0.39 ± 1.92 ± 1.71 ± 0.71
The average BMI of patients after 3 month were 26.58±1.75 in GROUP A with difference
of 1.05±0.39 from initial value 27.64 and 25.91±1.71 in GROUP B with difference of 1.08±0.71
from initial value 26.99. 
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Change in BMI
   Fig.no 4
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B. EFFICACY OF THE TWO REGIMENS 
Table 7:  Change in systolic blood pressure (SBP) – in mm Hg 
SBP Values at                         SBP Values         ‘p’ 
     Values   
        Group A            Group B
Mean SD Mean SD
First visit 152.93 6.53 148.80 7.28 0.02
Second visit 147.06 6.30 140.94 7.12 P<0.001
Third visit 142.87 6.50 134.06 7.11 P<0.001
Fourth visit 137.48 6.77 127.80 6.99 P<0.001
Fifth visit 131.14 6.6 122.00 6.90 P<0.001
Sixth visit 125.00 6.96 115.53 6.40 P<0.001
Decrease
(First visit – sixth 
visit)
27.94 3.09 33.27 3.42 P<0.001
The systolic blood pressure showed significant reduction in the both group. The reduction
was greater in GROUP B who was treated with Telmisartan 40 mg, than in GROUP A who were
treated with Losartan potassium 50 mg.
The mean systolic blood pressure reduction in GROUP B was (33.27±3.42) & GROUP A
was (27.94± 3.09) at the end of 3 months, which shows that the regimen B  have better impact on
systolic blood pressure than GROUP A with statistically significant  ‘p’ value  less than 0.001
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Change in systolic blood pressure (SBP)
Fig.no 5
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Change in systolic blood pressure in 2 week intervals.
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\The SBP values of GROUP A and GROUP B were initially 152.93±6.53 & 148.8±7.28
respectively  and  that  was  changed  to  147.06±6.30& 140.94±7.12  on  Second  visit  ,  then  it
changed to the levels of 142.87±6.50 &134.06±7.11, 137.48 ±6.77 & 127.8±6.99,  131.14±6.60
& 122±6.90, 125±6.96 & 115.53±6.40 in further third, fourth ,fifth ,sixth visits.
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Table 8: 
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DBP   Values 
at 
DBP Values         ‘p’ 
     Values   
Group A Group B
Mean SD Mean SD
First visit 93.73 3.39 93.27 2.75 0.561
Second visit 90.74 2.94 88.80 2.99 0.01
Third visit 87.33 2.53 85.14 3.18 0.004
 Fourth visit 85.60 2.75 82.54 3.32 P<0.001
Fifth visit 84.20 2.59 81.20 3.22 P<0.001
Sixth visit 82.20 2.53 78.80 3.13 P<0.001
Decrease
(First visit – 
sixth visit)
11.54 2.27 14.47 2.33 P<0.001
OBSERVATIONS AND RESULTS
The  diastolic  blood  pressure  showed  significant  reduction  in  the  both  group.  The
reduction was greater in GROUP B who was treated with telmisartan 40 mg, than in GROUP A
who are treated with losartan potassium 50 mg. 
Diastolic  blood  pressure  decreased  significantly  in  GROUP B (14.47± 2.33)  than  in
GROUP A (11.54 ± 2.27) at the end of 3 months, which showed that the regimen B  had a
significantly better impact on systolic blood pressure ( p< 0.05) than GROUP A. 
Change in diastolic blood pressure (DBP)
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      Fig.no. 7
Change in diastolic blood pressure in 2 week interval.
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Fig.no. 8
Initial  DBP  values  of  GROUP  A  and  GROUP  B  were
93.73±3.39&93.27±2.75respectively  and  that  was  changed  to  90.74±2.94  &  88.80±2.99  on
second  visit  ,  then  it  changed  to  the  levels  of  87.33±2.53  &  85.14±3.18,  85.60  ±2.75  &
82.54±3.32,84.20±2.59 & 81.27±3.32, 82.20±2.53 & 78.80±3.13 in further third, fourth,  fifth
and sixth visits.
FBS Values 
at
FBS Values
         ‘p’ 
Group A Group B
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     Values
Mean SD Mean SD
First visit
145.47 16.40 136 13.06 0.0163
Sixth visit 
138.06 15.83 123.16 13.32 0.0002
Decrease
(First visit – 
sixth visit)
7.40 1.35 12.83 4.86 0.0001
Table 9: Fasting blood sugar (FBS) Values
The fasting blood sugar  values reduced significantly in both groups,  the reduction of
fasting blood sugar was greater in Group B 12.83±4.86 than in Group A 7.40±1.35.
The Group B shows better significant reduction in fasting blood sugar than Group A at
the end of 3 month study with a p value of  <0.05.
Change in Fasting blood sugar (FBS)
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         Fig.no 9
Table 10: Change in Post prandial blood sugar (PPBS)
PPBS Values at
PPBS Values
         ‘p’ 
     Values
Group A Group B
Mean SD Mean SD
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First visit 247 21.81 247.87 17.02 0.8643
Sixth visit 229.81 19.92 217.47 15.81 0.0098
Decrease
(First visit – 
sixth visit)
17.14 3.69 30.40 8.92 0.0001
The PPBS values reduced significantly in both groups,  the reduction of fasting blood
sugar was greater in Group B 30.40±8.92 than in Group A 17.14±3.69.
The Group B shows better significant reduction in PPBS than Group A at the end of 3
month study with a p values<0.05.
Change in Post pradinal blood sugar (PPBS)
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Fig.no 10
Table 11: Change in Fasting Blood Sugar- FBS (Patients Treated with Metformin HCL 500 mg )
FBS Values at
Group A Group B P- Value
Mean SD Range Mean SD Range
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First visit 137.3 19.79 119-166 130.9 9.33 114-145 0.315
Sixth visit
130.9 19.77 113-160 120 10.78 102-137 0.105
Decrease(First
visit – sixth
visit)
6.4 0.97 5-8 10.92 1.89 8-14 P<0.001
           A total number of  11&13 patients who were under antidiabetic treatment with Metformin
HCl 500 mg belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and
were in hypertensive category Group  B respectively.
           The observed change in Fasting Blood Sugar value was from 137.3 ± 19.79 to 130.9
±19.77 with a mean decrease of 6.4 ± 0.97 in Group A, and that was from 130.9 ± 9.33 to 120 ±
10.78 in Group B with a mean decrease of 10.92 ± 1.89 Group B have better  reduction in FBS
than Group A. 
          
Change in Fasting Blood Sugar- FBS (Metformin HCL 500 mg)
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Fig.no 11
Table 12: Change in Post prandial Blood Sugar-PPBS (Patients Treated with Metformin 
HCL 500 mg)
PPBS Values
at
Group A Group B
P- ValueMean SD Range Mean SD Range
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First visit 229.8 19.86 200-256 245.77 16.74 215-274 0.048
Sixth visit 214.3 17.26 190-240 217.6 15.01 198-236 0.628
Decrease(First
visit – sixth
visit)
15.5 4.03 10-21 28.15 6.58 17-38 P<0.001
           A total number of 11&13 patients who were under antidiabetic treatment with Metformin
HCl 500 mg belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and
Group  B (Telmisartan 40 mg) respectively .
            The observed change in Post Prandial  Blood Sugar value was from 229.8 ± 19.86 to
214.3 ± 17.26 with a mean decrease of 15.5 ± 4.03 in Group A, and that was from 245.77 ± 16.74
to  217.6  ± 15.01  in  Group  B with  a  mean  decrease  of  28.15  ± 6.58  Group  B have  better
reduction in PPBS than Group A. 
Change in Post Prandial Blood Sugar-PPBS (Metformin HCL 500 mg)
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                                                      Fig.no 12
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Table 13: Change in Fasting Blood Sugar-FBS (Patients Treated with Glimepiride 1 mg+ 
Metformin HCL 500 mg)
  
FBS Values at
  
Group A Group B
  
   P- Value Mean SD Range Mean SD Range
First visit 150.28 12.84 130-167 143 16.85 120-180 0.3597
Sixth visit 142 12.61 122-158 127.11 18.65 107-165 0.0921
Decrease(First
visit – sixth
visit)
8.28 1.11 7-10 15.88 7.47 11-32 0.02
          A total number of 7&9 patients who were under antidiabetic treatment with Metformin
HCl 500 mg + Glimepiride 1 mg, belong to hypertensive patient category  Group A ( Losartan
Potassium 50 mg ) and Group  B(telmisartan 40 mg) respectively.
           The observed change in Fasting Blood Sugar value was from 150.28 ± 12.84 to142 ±
12.61 with  a  mean  decrease  of  8.28  ± 1.11in Group A,  and that  was from 143  ± 16.85 to
127.11±18.65 in Group B with a mean decrease of 15.88 ±  Group B have better  reduction in
FBS than Group A. 
Change in Fasting Blood Sugar-FBS (Glimepiride 1 mg+ Metformin HCL 500 mg)
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Fig.no 13
Table 14: Change in Post prandial Blood Sugar-PPBS (Patients Treated with Glimepiride 1 
mg+ Metformin HCL 500 mg )
    FBS Values 
at Group A Group B
     
  P- Value 
Mean SD Range Mean SD Range
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First visit 262 13.35 130-167 253.56 15.63 220-270 0.2581
Sixth visit 245 11.46 122-158 216.4 13.65 200-246 P<0.001
Decrease(Firs
t visit – sixth
visit)
17.28 3.59 7-10 37.11 9.94 20-49 P<0.001
          A total number of 7&11 patients who were under antidiabetic treatment with Glimepride 1
mg + Metformin HCl 500 belong to hypertensive patient category  Group A ( Losartan Potassium
50 mg ) and  Group  B (telmisartan 40 mg) respectively.
           The observed change in Post Prandial  Blood Sugar value was from 262 ± 13.35 to 245 ±
11.46 with a mean decrease of17.28 ± 3.59 in Group A, and that was from 253.56 ± 15.63  to
216.4 ± 13.65  in Group B with a mean decrease of 37.11 ± 9.94.Group B have better  reduction
in PPBS than Group A. 
Change in Post Prandial Blood Sugar-PPBS (Glimepiride 1 mg+ Metformin HCL 500 mg)
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Fig.no 14
Table 15: Change in Fasting Blood Sugar-FBS  (Patients Treated with Glimepiride 1 mg)
     FBS Values
at Group A Group B
     
  P- Value 
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Mean SD Range Mean SD Range
First visit 155.43 16.19 129-180 132.4 6.06 124-140 0.013
Sixth visit 147.57 15.05 124-170 119.8 6.02 114-128 0.003*
Decrease(Firs
t visit – sixth
visit)
7.85 1.77 5-10 12.6 2.61 9-16 0.0036*
         A total number of 7&5 patients who were under antidiabetic treatment with Glimepiride 1
mg were belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and
Group B (telmisartan 40 mg) respectively.
         The observed change in Fasting Blood Sugar value was from 155.43 ± 16.19 to 147.57 ±
15.05 with a mean decrease of 7.85 ± 1.77 in Group A, and that was from 132.4 ± 6.06  to 119.8
±6.02  in Group B with a mean decrease of 12.6 ± 2.61 Group B have better  reduction in FBS
than Group A. 
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Change in Fasting Blood Sugar-FBS (Glimepiride 1 mg)
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Fig.nlo 15
Table 16: Change in Post prandial Blood Sugar (Patients Treated with Glimepiride 1 mg))
   
  PPBS Values 
Group A Group B
     
  P- Value 
Mean SD Range Mean SD Range
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at
First visit 256.14 23.31 219-279 236.8 15.62 210-250 0.139
Sixth visit 237 22.42 202-264 209.8 17.21 190-236 0.046
Decrease(First 
visit – sixth 
visit)
19.14 3.71 15-24 27 9.94 14-39 0.081
           A total number of 7&5 patients  who were under antidiabetic treatment with Glimepiride 1
mg  belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and  were
Group  B (telmisartan 40 mg) respectively.
           The observed change in Post Prandial Blood Sugar value was from 256.14 ± 23.31 to 237
± 22.42 with a mean decrease of 19.14 ± 3.71 in Group A, and that was from 236.8 ± 15.62 to
209.8 ± 17.21 in Group B with a mean decrease of 27 ± 9.94. Group B have better reduction in
PPBS than Group A. 
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Fig.no 16
Table 17: Change in Fasting Blood Sugar (Patients Treated with Voglibose 0.2 mg)
     FBS Values
Group A Group B
       P- Value 
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at Mean SD Range Mean SD Range
First visit 142.5 2.12 141-144 154 - 154 -
Sixth visit 135 2.82 133-137 137 - 137 -
Decrease(Firs
t visit – sixth 
visit)
7.5 0.71 7-8 17 - 17 -
           A total number of 2&1 patients who were under antidiabetic treatment with Voglibose 0.2
mg  belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and Group
B (telmisartan 40 mg) respectively.
           The observed change in Fasting Blood Sugar value was from 142.5 ± 2.12 to 135 ± 2.82
with a mean decrease of 7.5 ± 0.71 in Group A, and that was from 154 to 137 in Group B with a
mean decrease of 17. Group B have better reduction in FBS than Group A. 
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Change in Fasting Blood Sugar-FBS (Voglibose 0.2 mg)
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Fig.no 17
 Table 18: Change in Post prandial Blood Sugar (Patients Treated with Voglibose 0.2 mg) )
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  PPBS Values
at
Group A Group B        P- Value 
Mean SD Range Mean SD Range
First visit 259 1.41 258-260 270 - 270 -
Sixth visit 241.5 2.12 240-243 246 - 246 -
Decrease(Firs
t visit – sixth 
visit)
17.5 3.53 15-20 24 - 24 -
           A total number of 2&1 patients who were under antidiabetic treatment with Voglibose 0.2
mg belong to hypertensive patient category  Group A ( Losartan Potassium 50 mg ) and Group  B
(telmisartan 40 mg) respectively.
           The observed change in Post Prandial Blood Sugar value was from 259 ± 1.41 to 241.5 ±
2.12 with a mean decrease of 17.5 ± 3.53 in Group A, and that was from 270 to 246 in Group B
with a mean decrease of 24. Group B have better reduction in PPBS than Group A. 
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Fig.no 18
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Table 19:Change in Fasting Blood Sugar (Patients Treated with Metformin HCL 500+ 
Voglibose 0.2 mg)) 
    FBS Values 
at
Group A Group B        P- Value 
Mean SD Range Mean SD Range
First visit 139 3.46 137-143 137.5 17.68 125-150 0.886
Sixth visit 131.7 3.79 129-136 127.5 16.26 116-139 0.675
Decrease(Firs
t visit – sixth 
visit)
7.33 0.58 7-8 10 1.41 9-11 0.053
         A total number of 3&2 patients  who were under antidiabetic treatment with Metformin
HCl 500 mg + Voglibose 0.2 mg belong to hypertensive patient category  Group A ( Losartan
Potassium 50 mg ) and Group  B (telmisartan 40 mg) respectively.
           The observed change in Fasting Blood Sugar value was from 139 ± 3.46 to 131.7 ± 3.79
with a mean decrease of 7.33 ± 0.58 in Group A, and that was from 137.5 ± 17.68 to 127.5 ±
16.26in Group B with a mean decrease of 10 ± 1.41. Group B have better reduction in FBS than
Group A. 
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Table 20: Change in Post prandial Blood Sugar (Patients Treated with Metformin HCL 500
mg + Voglibose 0.2 mg)) 
    Group A Group B        P- Value 
Mean SD Range Mean SD Range
First visit 238.3 10.41 230-250 252.5 24.75 235-270 0.419
Sixth visit 221 7.54 214-229 226 24.04 209-243 0.742
Decrease(Firs
t visit – sixth 
visit)
17.33 3.21 15-21 26.5 0.71 26-27 0.032*
           A total number of 3&2 patients who were under antidiabetic treatment with Metformin
HCl 500 mg + Voglibose 0.2 mg  belong to hypertensive patient category  Group A ( Losartan
Potassium 50 mg ) and  Group  B (telmisartan 40 mg) respectively.
           The observed change in Post Prandial  Blood Sugar value was from 238.3 ± 10.41 to 221
± 7.54 with a mean decrease of 17.33 ± 3.21 in Group A, and that was from 252.5 ± 24.75 to 226
± 24.04 in Group B with a mean decrease of 26.5 ± 0.71 Group B have better  reduction in PPBS
than Group A. 
Ultra College of Pharmacy, Madurai. Page 81
OBSERVATIONS AND RESULTS
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8. DISCUSSION
Angiotensin  II  receptor  antagonists  provide  a  more  specific  blockade  to  the  renin-
angiotensin system and have better tolerability when compared with ACE inhibitors. In addition,
the evidence available thus far for this new class of antagonists has established that their efficacy
is equal to that of ACE inhibitors in hypertension. Therefore, it is conceivable that angiotensin II
receptor  blockers  will  take  a  growing  place  in  the  management  of  hypertensive  patients.
However, the place of angiotensin II receptor antagonists in the management of hypertension
will of course, depend on the results of morbidity and mortality trials.
In this study comparison of efficacy of Losartan and Telmisartan in hypertensive patients
was carried out.  Patients with hypertension were enrolled for the study as  per inclusion and
exclusion criteria. They are divided into Group A (30 patients who were treated with Losartan
potassium 50  mg)  &Group B (30  patients  who were  treated  with  Telmisartan  40  mg).  The
parameters that used tothe efficacy comparison were - SBP, DBP, and FBS& PPBS. SBP & DBP
were recorded from baseline to three months in an interval of 15 days. And the FBS & PPBS
were recorded in the base line and at the end of the study. Then the comparison was done with
the help of computational statistical method.  
 In  this prospective study we observed that  both Losartan potassium and Telmisartan
reduces the blood pressure. Telmisartan was significantly superior to losartan in reduction of the
Systolic blood pressure& Diastolic blood pressure with a p value(< 0.05) and Telmisartan the
same shows superior reduction blood sugar levels than Losartan potassium with significant p
value <0.05. 
AGE:
A number of 60 patients were enrolled for the study and their age distribution was as
below -
30 patients were of group A, out of these 3 patients (10%) between the age group of 30-
39 years,  11 patients (36.66%) between the age group of 40-49 years,  16 patients (53.34%)
between the age group of 50-60 years,
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Out of 60 patients, 30 patients were of group A, out of these 2 patients (6.67%) between
the age group of  30-39 years,  12 patients  (40%) between the age  group of  40-49 years,  16
patients (53.33%) between the age group of 50-60 years,
The age group A was 50.17± 6.62 years and group B was 50.34 ± 6.25 years. A total
number  of  32 patients  comes under  the age  category 50-60 years  ie,  53.33% of total  study
population this will cement the age correlation of hypertension “ As the age increases the risk for
hypertension also increases”
SEX: 
A total of 60 patients were screened and randomized into two treatment group. Out of
which 30 patients were of GROUP A, 18 patients (60%) were male, 12 patients (40%) were
female.  In  case of  GROUP B,  20,  patients  (66.67%) were male,  10 patients  (33.34%) were
female.
In  our  study  population,  numbers  of  males  with  hypertension  were  higher  than  the
females, this may be due to the life style difference between the males and females, especially
using of tobacco and alcohol. 
PHYSIOLOGICAL PARAMETERS:
The average weights of patients were 74.1±5.97 in GROUP A and 70.57±5.84 in GROUP
B. The average BMI of patients were 27.64±1.73 in GROUP A and 26.99±1.92 in GROUP B.
The  was  no  statistically  significant  difference  in  the  mean  weight  and  BMI of  two groups
(P>0.05)
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SYSTOLIC BLOOD PRESSURE:
The mean systolic blood pressure of Group A and Group B were (152.93±6.53mm Hg&
148.8±7.28 mm Hg) respectively, at the base line (First visit). The group A who were treated
with Losartan potassium 50 mg showed a mean reduction of (27.94± 3.09mm Hg) but that was
lower than that produced by the Telmisartan in Group B (33.27± 3.42 mm Hg).
Both of the study drug produced reduction in the systolic blood pressure during the study
time and of  that,  the Telmisartan 40 mg is  found to be  superior  in SBP reduction which is
statistically significant when compare to Losartan potassium 50 mg with a  p value <0.05. 
DIASTOLIC BLOOD PRESSURE:
The mean Diastolic blood pressure of Group A and Group B were (93.73±3.39mm Hg &
93.27± 2.75 mm Hg) respectively, at the base line (First visit). The group A who were treated
with Losartan potassium 50 mg showed a mean reduction of (11.54± 2.27 mm Hg) but that was
lower than that produced by the Telmisartan 40 mg in Group B (14.47± 2.33 mm Hg).
Both of the study drug produced reduction in the systolic blood pressure during the study
time and  of  that  the  Telmisartan  40 mg is  found to  be  superior  in  SBP reduction  which is
statistically significant when compare to Losartan potassium 50 mg with a  p value <0.05.
EFFECT OF STUDY DRUGS IN BLOOD SUGAR LEVELS OF STUDY POPULATION
FASTING BLOOD SUGAR(FBS)
The fasting blood sugar values reduced in both groups, the reduction of fasting blood
sugar  was  greater  in  Group  B(Telmisartan  40  mg)12.83±4.86  than  in  Group  A (Losartan
potassium 50 mg) 7.40±1.35.
The Group B shows better  reduction in fasting blood sugar than Group A at the end of 3
month study with a statistically significant p value of  <0.05.
The fasting blood sugar changes among the study population who were under different
anti diabetic therapy was observed as follows;
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Metformin HCL 500 mg:
Values  were  decreased  from base  line  value  137.3  ± 19.79 to  130.9  ± 19.77  with  a
decrease of 6.4 ± 0.97 in Group A and in Group B it was from base line value 130.9 ± 9.33 to
120 ± 10.78 with a decrease of 10.92 ± 1.89. It was found to be higher reduction in Group B than
in Group A. 
Metformin HCL 500 mg + Glimepiride 1 mg:
Values  were  decreased  from base  line  value  150.28  ± 12.84  to  142  ± 12.61  with  a
decrease of 8.28 ± 1.11 in Group A and in Group B it was from base line value 143 ± 16.85 to
127.11 ± 18.65 with a decrease of 15.88 ± 7.47. It was found to be higher reduction in Group B
than in Group A.
Glimepiride 1 mg:
Values were decreased from base line value 155.43 ± 16.19 to 147.57 ± 15.05 with a
decrease of 7.85 ± 1.77 in Group A and in Group B it was from base line value 132.4 ± 6.06 to
119.8 ± 6.02 with a decrease of 12.6 ± 2.61. It was found to be higher reduction in Group B than
in Group A .
Voglibose 0.2 mg:
Values were decreased from base line value 142.5 ± 2.12 to 135 ± 2.82 with a decrease of
7.5 ± 0.71 in Group A and in Group B it was from base line value 154 to 137 with a decrease of
17. It was found to be higher reduction in Group B than in Group A.
Metformin HCL 500 mg + Voglibose 0.2 mg:
Values were decreased from base line value 139 ± 3.46 to 131.7 ± 3.79 with a decrease of
7.33 ± 0.58 in Group A and in Group B it was from  base line value 137.5  ± 17.68 to 127.5 ±
16.26 with a decrease of 10 ± 1.41. It was found to be higher reduction in Group B than in Group
A.
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POST PRANDIAL BLOOD SUGAR (PPBS)
The PPBS values reduced in both groups, the reduction of post prandial blood sugar was
greater in Group B(Telmisartan 40 mg) 30.40±8.92 than in Group A (Losartan potassium 50
mg)17.14±3.69.
The Group B shows better significant reduction in PPBS than Group A at the end of 3
month study with a p values<0.05.
From the above findings it can assess that the partial PPAR-gamma activity of telmisartan
sounds for the superior reduction in blood sugar values.   
The  post  prandial  blood  sugar  changes  among the  study population who were  under
different anti diabetic therapy were observed as follows;
Metformin HCL 500 mg:
Values  were  decreased  from base  line  value  229.8  ± 19.86 to  214.3  ± 17.26  with  a
decrease of 15.5 ± 4.03 in Group A and in Group B it was from base line value 245.77 ± 16.74 to
217.6 ±15.01 with a decrease of 28.15 ± 6.58. It was found to be higher reduction in Group B
than in Group A.
Metformin HCL 500 mg + Glimepiride 1 mg:
Values were decreased from base line value 150.29 ± 12.84 to 142 ± 12.61with a decrease
of 8.28 ± 1.11 in Group A and in Group B it was from base line value 253.56 ± 15.63 to 216.4 ±
13.65 with a decrease of 37.11 ± 9.94. It was found to be higher reduction in Group B than in
Group A.
Glimepiride 1 mg:
Values  were  decreased  from base  line  value  256.14  ± 23.31  to  237  ± 22.42  with  a
decrease of 19.14 ± 3.71 in Group A and in Group B it was from  base line value 236.8 ± 15.62
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to 209.8 ± 17.21 with a decrease of 27 ± 9.94. It was found to be higher reduction in Group B
than in Group A.
Voglibose 0.2 mg: 
Values were decreased from base line value 259 ±1.41 to 241.5 ± 2.12 with a decrease of
17.5 ± 3.53 in Group A and in Group B it was from  base line value 270 to 246 with a decrease of
24. It was found to be higher reduction in Group B than in Group A.
Metformin HCL 500 mg + Voglibose 0.2 mg:
Values were decreased from base line value 238.3 ± 10.41to 221 ± 7.54 with a
decrease of 17.33 ± 3.21 in Group A and in Group B it was from base line value  252.5 ± 24.75
to 226 ± 24.O4 with a decrease of 26.5 ± 0.71. It was found to be higher reduction in Group B
than in Group A.
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9.CONCLUSION
In this present prospective observational study, treatment of hypertension with two study
drugs losartan potassium 50 mg and telmisartan 40 mg were carried out in a population of 60
patients. They were instructed to follow a healthy diet with proper exercise. 
After 3 months study it is observed that, both of the study drugs have good impact on
blood pressure lowering. But the Telmisartan 40 mg showed superior reduction in blood pressure
when compare to Losartan potassium 50 mg.
The second objective of the study ie; effect of study drugs Losartan potassium 50 mg and
telmisartan 40 mg in blood sugar levels of population on diabetic therapy. The FBS and PPBS
were the parameters observed for the study, there was reduction in FBS and PPBS values in both
Group A Group B. And it is observed that the reduction is higher in Group B when compare with
Group A.  It  can  be  suggested  that  the  partial  PPAR gamma agonist  activity of  Telmisartan
accounts for the higher reduction in blood sugar levels.
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PROFORMA
COMPARATIVE STUDY ON EFFICACY OF LOSARTAN VERSUS
TELMISARTAN IN HYPERTENSIVE PATIENTS
DEMOGRAPHICDATA  :
1. NAME:                                                              2. AGE:                     3. SEX: M/F                   4: OPNO:  
5. WEIGHT:                                                            6. HEIGHT:                  7. BMI:
7. ADDRESS:                                     
8. PATIENT HISTORY:                       
9. DIAGNOSIS:
10. DRUG USED: LOSARTAN POTASSIUM 50 MG          
                                TELMISARTAN 40 MG                   
11. OTHER CO-MORBIDITIES:        
12. OTHER DRUGS USED:
BASE LINE( First visit)
DATE:    
PARAMETERS
PRIMARY 
SYSTOLIC BLOOD PRESSURE: mm Hg
DIASTOLIC BLOOD PRESSURE:mm Hg
SECONDARY
FBS:
PPBS:
SECOND VISIT                                                                DATE:      
PARAMETERS
 SYSTOLIC BLOOD PRESSURE: mm Hg
DIASTOLIC BLOOD PRESSURE:mm Hg
THIRD VISIT DATE:  
PARAMETERS
 SYSTOLIC BLOOD PRESSURE: mm Hg
DIASTOLIC BLOOD PRESSURE:mm Hg
FOURTH VISIT DATE:  
PARAMETERS
 SYSTOLIC BLOOD PRESSURE: mm Hg
DIASTOLIC BLOOD PRESSURE:mm Hg
FIFTH VISIT DATE:  
PARAMETERS
 SYSTOLIC BLOOD PRESSURE: mm Hg
DIASTOLIC BLOOD PRESSURE:mm Hg
SIXTH VISIT DATE:  
PARAMETERS
PRIMARY SECONDARY  
SYSTOLIC BLOOD PRESSURE: mm Hg FBS:
DIASTOLIC BLOOD PRESSURE:mm Hg PPBS:
Body weight:      Kg
Pharmacist signature  Physician signature
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